89,566 Shares in Collegium Pharmaceutical, Inc. $COLL Bought by Nuveen LLC

Key Points

• Nuveen LLC has made a new investment in Collegium Pharmaceutical, purchasing approximately $2.67 million worth of shares, which represents about 0.28% ownership in the company.
• Collegium Pharmaceutical's stock has received multiple upgrades from analysts, with HC Wainwright and Wall Street Zen both rating the stock as a "strong-buy" and setting price targets above $42.
• The company has initiated a stock repurchase plan for up to $150 million, suggesting that the board believes its shares may be undervalued.

Nuveen LLC acquired a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the first quarter, according to its most recent filing with the SEC. The fund acquired 89,566 shares of the specialty pharmaceutical company's stock, valued at approximately $2,674,000. Nuveen LLC owned approximately 0.28% of Collegium Pharmaceutical at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Collegium Pharmaceutical by 1.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company's stock valued at $522,000 after buying an additional 339 shares in the last quarter. SummerHaven Investment Management LLC grew its stake in Collegium Pharmaceutical by 1.9% in the 1st quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company's stock valued at $727,000 after buying an additional 448 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Collegium Pharmaceutical by 4.5% in the 1st quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company's stock valued at $326,000 after buying an additional 477 shares in the last quarter. Virtus Fund Advisers LLC grew its stake in Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 565 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in Collegium Pharmaceutical by 4.2% in the 1st quarter. SG Americas Securities LLC now owns 14,277 shares of the specialty pharmaceutical company's stock valued at $426,000 after buying an additional 578 shares in the last quarter.

Insider Activity at Collegium Pharmaceutical

In related news, Director Gino Santini sold 5,405 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $37.19, for a total value of $201,011.95. Following the completion of the transaction, the director directly owned 95,042 shares in the company, valued at approximately $3,534,611.98. The trade was a 5.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas B. Smith sold 17,478 shares of the company's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $38.42, for a total transaction of $671,504.76. Following the completion of the transaction, the executive vice president owned 70,264 shares of the company's stock, valued at $2,699,542.88. This trade represents a 19.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,393 shares of company stock valued at $2,286,330 over the last ninety days. 2.51% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. HC Wainwright upgraded shares of Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 price target for the company in a research report on Monday, August 11th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 price target (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $42.33.

Collegium Pharmaceutical Price Performance

Shares of COLL traded up $0.43 during trading hours on Wednesday, reaching $39.59. 542,978 shares of the company's stock traded hands, compared to its average volume of 429,310. The stock has a market cap of $1.25 billion, a PE ratio of 38.07 and a beta of 0.63. The company has a current ratio of 1.18, a quick ratio of 1.10 and a debt-to-equity ratio of 3.27. The firm's 50 day simple moving average is $33.87 and its 200-day simple moving average is $30.50. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $42.29.

Collegium Pharmaceutical declared that its Board of Directors has initiated a stock repurchase program on Monday, July 7th that authorizes the company to repurchase $150.00 million in shares. This repurchase authorization authorizes the specialty pharmaceutical company to purchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its shares are undervalued.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.